Evidence map›Paper›PMID 30713767›Full record

ArticleActa naturae

The TLR4 Agonist Immunomax Affects the Phenotype of Mouse Lung Macrophages during Respiratory Syncytial Virus Infection.

A A Nikonova, A V Pichugin, M M Chulkina, E S Lebedeva, A R Gaisina, I P Shilovskiy, R I Ataullakhanov, M R Khaitov, R M Khaitov

Open access · hybridAbstract read

PubMed Full text at PMC

In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

1.0field-weighted citation impact, top 23% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

M1-like, but not M0- or M2-like, macrophages, reduce RSV infection of primary bronchial epithelial cells in a media-dependent fashion.PloS one · 2022
Article
Immunopathology of RSV: An Updated Review.Viruses · 2021
Review
M1-like macrophages are potent producers of anti-viral interferons and M1-associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma exacerbations.EBioMedicine · 2020
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

A A NikonovaNRC Institute of Immunology FMBA of Russia, Kashirskoe shosse, 24, Moscow, 115478, Russia.

A V PichuginNRC Institute of Immunology FMBA of Russia, Kashirskoe shosse, 24, Moscow, 115478, Russia.

M M ChulkinaNRC Institute of Immunology FMBA of Russia, Kashirskoe shosse, 24, Moscow, 115478, Russia.

E S LebedevaNRC Institute of Immunology FMBA of Russia, Kashirskoe shosse, 24, Moscow, 115478, Russia.

A R GaisinaNRC Institute of Immunology FMBA of Russia, Kashirskoe shosse, 24, Moscow, 115478, Russia.

I P ShilovskiyNRC Institute of Immunology FMBA of Russia, Kashirskoe shosse, 24, Moscow, 115478, Russia.

R I AtaullakhanovNRC Institute of Immunology FMBA of Russia, Kashirskoe shosse, 24, Moscow, 115478, Russia.

M R KhaitovNRC Institute of Immunology FMBA of Russia, Kashirskoe shosse, 24, Moscow, 115478, Russia.

R M KhaitovNRC Institute of Immunology FMBA of Russia, Kashirskoe shosse, 24, Moscow, 115478, Russia.

Research Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the study, the effect of the TLR4 agonist Immunomax was investigated

Indexed as

bronchial asthmamacrophagesPRRrespiratory syncytial virusTLR4 agonists

Identifiers

PMID30713767

PMCPMC6351037

OpenAlexW2922775540

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.